Editorial update — September 11, 2026: The original version of this 2024 announcement used promotional terms such as “breakthrough,” “groundbreaking” and “revolutionary,” and described proof-of-concept findings as though they established real-world product performance. Those statements have been withdrawn. This page now summarizes the historical update using narrower research language.
What the research evaluated
miRoncol reported proof-of-concept work evaluating whether patterns of circulating cell-free microRNAs in previously collected blood samples could distinguish samples from people with certain solid-tumour cancers from non-cancer samples. Machine-learning methods were used to develop and evaluate research models.
The cited work was retrospective and case-control in design. It did not establish prospective population-screening performance, clinical utility, mortality benefit, affordability, accessibility or performance of a later commercial laboratory service.
Published research-model results
Peer-reviewed studies were published in Cancers in 2022 and Scientific Reports in 2024. Reported sensitivity and specificity apply to the study datasets, models, specimen conditions and thresholds described in those publications. Results varied by cancer type and should not be interpreted as an individual prediction or a guarantee.
The 2024 Nobel Prize in Physiology or Medicine recognized the discovery of microRNA and its role in post-transcriptional gene regulation. It did not evaluate or endorse miRoncol, miCheckup or any product.
Current context
miRoncol continues research and development involving microRNA measurement and analysis. Research applications may be at different stages of validation and regulatory readiness. A disease-associated signal is not a diagnosis, and no suspected signal does not rule out disease. Current service details, limitations and availability should be confirmed on the applicable product website and with the responsible clinical team.